Founded in 2018 and based in New York, Magnolia Neurosciences develops proprietary therapeutics and drug-like small molecule neuroprotective medicines to treat neurodegeneration and neuronal injuries. The company aims to target the underlying mechanisms of these diseases, which have been an area of substantial unmet medical need. By preventing neuronal cell death, Magnolia Neurosciences provides novel treatment options for patients suffering from neurodegenerative diseases.